National Institute of Diabetes and Digestive and Kidney Diseases Notice of Closed Meeting, 63315-63316 [2011-26215]
Download as PDF
<![CDATA[
Federal Register / Vol. 76, No. 197 / Wednesday, October 12, 2011 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
jlentini on DSK4TPTVN1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Overflow:
Cancer Therapeutics.
Date: October 17, 2011.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: Embassy Suites at the Chevy Chase
Pavilion, 4300 Military Road, NW.,
Washington, DC 20015.
Contact Person: Careen K Tang-Toth, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6214,
MSC 7804, Bethesda, MD 20892, (301) 435–
3504, tothct@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, PAR–11–
216: Early Phase Clinical Trials in Imaging
and Image-Guided Interventions.
Date: November 1, 2011.
Time: 1 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
Contact Person: David L Williams, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5110,
MSC 7854, Bethesda, MD 20892, (301) 435–
1174, williamsdl2@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Translational Research in Diabetes, Obesity
and Endocrinology.
Date: November 2, 2011.
Time: 8 a.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Virtual Meeting).
VerDate Mar<15>2010
17:43 Oct 11, 2011
Jkt 226001
Contact Person: Nancy Sheard, SCD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6046–E,
MSC 7892, Bethesda, MD 20892, 301–408–
9901, sheardn@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Synthetic
and Biological Chemistry.
Date: November 2, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Palomar, 2121 P Street, NW.,
Washington, DC 20037.
Contact Person: Kathryn M. Koeller, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040N,
MSC 7806, Bethesda, MD 20892, 301–408–
9333, koellerk@csr.nih.gov.
Name of Committee: Biological Chemistry
and Macromolecular Biophysics Integrated
Review Group, Synthetic and Biological
Chemistry A Study Section.
Date: November 2, 2011.
Time: 8 a.m. to 7 p.m.
Agenda: To review and evaluate grant
applications.
Place: Hotel Palomar, 2121 P Street, NW.,
Washington, DC 20037.
Contact Person: Mike Radtke, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4176,
MSC 7806, Bethesda, MD 20892, 301–435–
1728, radtkem@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Drug
Discovery for the Nervous System II.
Date: November 2, 2011.
Time: 1 p.m. to 3 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Geoffrey G Schofield, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4040–A,
MSC 7850, Bethesda, MD 20892, 301–435–
1235, geoffreys@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Small
Business: Visual Systems.
Date: November 3–4, 2011.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Morrison-Clark Inn, 1015 L Street,
NW., Washington, DC 20001.
Contact Person: Joseph G Rudolph, PhD,
Chief and Scientific Review Officer, Center
for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5186,
MSC 7844, Bethesda, MD 20892, 301–408–
9098, josephru@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Bone
Biology, Periodontal Disease and Tissue
Engineering.
Date: November 3, 2011.
Time: 4:30 p.m. to 6 p.m.
Agenda: To review and evaluate grant
applications.
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
63315
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892,
(Telephone Conference Call).
Contact Person: Priscilla B Chen, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4104,
MSC 7814, Bethesda, MD 20892, (301) 435–
1787, chenp@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: October 3, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2011–26222 Filed 10–11–11; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases Notice
of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel, HEV Ancillary
Study.
Date: November 17, 2011,
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications,
Place: National Institutes of Health, Two
Democracy Plaza, 6707 Democracy
Boulevard, Bethesda, MD 20892, (Telephone
Conference Call).
Contact Person: D. G. Patel, PhD, Scientific
Review Officer, Review Branch, DEA,
NIDDK, National Institutes of Health, Room
756, 6707 Democracy Boulevard, Bethesda,
MD 20892–5452, (301) 594–7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
E:\FR\FM\12OCN1.SGM
12OCN1
63316
Federal Register / Vol. 76, No. 197 / Wednesday, October 12, 2011 / Notices
and Hematology Research, National Institutes
of Health, HHS)
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Dated: October 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory
Committee Policy.
National Institutes of Health
Prospective Grant of Exclusive
License: Secreted Frizzled Related
Protein-1 (sFRP–1) and derivatives
thereof and their Use In Therapeutic
Applications
[FR Doc. 2011–26215 Filed 10–11–11; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
SUMMARY:
Filing date or
international
filing date
Status
Publication or
patent number
Abandoned .........................................................
Abandoned .........................................................
Issued ................................................................
Issued ................................................................
Expired ...............................................................
Issued ................................................................
Issued ................................................................
Issued ................................................................
Pending ..............................................................
Abandoned .........................................................
Expired ...............................................................
Issued ................................................................
Pending ..............................................................
Issued ................................................................
Pending ..............................................................
Pending ..............................................................
Issued ................................................................
Issued ................................................................
Issued ................................................................
N/A
N/A
6,479,255
7,183,377
WO 98/54325
6,600,018
7,223,853
7,947,651
N/A
N/A
WO 02/055547
7,488,710
20080145884 A1
2002241859
2,434,672
1387854 A2
4029041
4248583
4248600
Country
60/050,417 .........................................................
60/050,495 .........................................................
09/087,031 .........................................................
10/138,434 .........................................................
PCT/US98/10974 ...............................................
09/546,043 .........................................................
10/425,586 .........................................................
11/748,872 .........................................................
13/031,060 .........................................................
60/260,908 .........................................................
PCT/US02/00869 ...............................................
10/466,136 .........................................................
12/019,567 .........................................................
2002241859 .......................................................
2,434,672 ...........................................................
02 707454.1 .......................................................
2002–556615 .....................................................
2007–120533 .....................................................
2008–169716 .....................................................
jlentini on DSK4TPTVN1PROD with NOTICES
Patent application number
US ......
US ......
US ......
US ......
PCT ....
US ......
US ......
US ......
US ......
US ......
PCT ....
US ......
US ......
AU ......
CA ......
EP ......
JP .......
JP .......
JP .......
to Achelois BioSciences, Inc., a
Delaware corporation having a place of
business in Lexington, Massachusetts.
The patent rights in these inventions
have been assigned to the United States
of America. In addition, the all of the
rights associated with applications 09/
546,043; 10/425,586; 11/748,872 and
13/031,060 are exclusively licensed to
HHS by the co-owner the University of
Massachusetts.
The prospective exclusive license
territory may be ‘‘worldwide’’, and the
field of use may be limited to ‘‘use of
sFRP–1 and derivatives thereof in the
treatment of human disease.’’
DATES: Only written comments and/or
applications for a license which are
received by the NIH Office of
Technology Transfer on or before
November 14, 2011 will be considered.
ADDRESSES: Requests for copies of the
patent applications, inquiries,
comments, and other materials relating
to the contemplated exclusive license
should be directed to: Susan S. Rucker,
JD, CLP, Senior Advisor for Intellectual
Property Transactions, Office of
Technology Transfer, National Institutes
of Health, 6011 Executive Boulevard,
Suite 325, Rockville, MD 20852–3804;
Telephone: (301) 435–4478; Facsimile:
(301) 402–0220; E-mail:
ruckersu@mail.nih.gov.
VerDate Mar<15>2010
17:43 Oct 11, 2011
Jkt 226001
5/29/1997
6/23/1997
5/29/1998
5/3/2002
5/29/1998
4/10/2000
4/28/2003
5/15/2007
2/18/2011
1/10/2001
1/10/2002
7/10/2003
1/24/2008
1/10/2002
1/10/2002
1/10/2002
1/10/2002
1/10/2002
1/10/2002
The
technology encompassed by the patents
and/or patent applications (IP) to be
included in this exclusive license
relates to a protein designated secreted
Frizzled Related Protein-1 (sFRP–1).
sFRP–1, also known as SARP–2
(Secreted Apoptosis Related Protein-2).
The IP covers various sFRP–1
compositions and uses thereof.
sFRP–1 is associated with Wnt
signaling which has been implicated in
a number of different processes
including fibrosis (see, Hwang, I et al.
Arch Pharm Res 32(12): 1653–62 (2009))
and bone remodeling (see, Hausler KD
et al J Bone Miner Res 19(11) 1873–81
(Nov 2004). In addition,
hypermethylation of the sFRP–1
promoter region, which leads to a loss
of function and decreased sFRP–1
protein expression, has been linked to a
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00039
Fmt 4703
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in the patents and patent
applications belonging to the patent
families having HHS Reference
Numbers E–160–1997/0,/1,/2 and/3; E–
014–2000/0; and E–060–2000/0, and/1.
Specific details regarding the individual
patents or patent applications which
belong to these patent families are set
forth in the table below:
Sfmt 4703
number of cancers, including gastric
cancer, esophageal adenocarcinoma,
bladder cancer and head and neck
squamous cell carcinoma (HNSCC).
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404.7. The
prospective exclusive license may be
granted unless within thirty (30) days
from the date of this published notice,
the NIH receives written evidence and
argument that establishes that the grant
of the license would not be consistent
with the requirements of 35 U.S.C. 209
and 37 CFR part 404.7.
Applications for a license in the field
of use filed in response to this notice
will be treated as objections to the grant
of the contemplated exclusive license.
Comments and objections submitted to
this notice will not be made available
for public inspection and, to the extent
permitted by law, will not be released
under the Freedom of Information Act,
5 U.S.C. 552.
E:\FR\FM\12OCN1.SGM
12OCN1
]]>Agencies
[Federal Register Volume 76, Number 197 (Wednesday, October 12, 2011)]
[Notices]
[Pages 63315-63316]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2011-26215]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and Digestive and Kidney Diseases
Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute of Diabetes and Digestive
and Kidney Diseases Special Emphasis Panel, HEV Ancillary Study.
Date: November 17, 2011,
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant applications,
Place: National Institutes of Health, Two Democracy Plaza, 6707
Democracy Boulevard, Bethesda, MD 20892, (Telephone Conference
Call).
Contact Person: D. G. Patel, PhD, Scientific Review Officer,
Review Branch, DEA, NIDDK, National Institutes of Health, Room 756,
6707 Democracy Boulevard, Bethesda, MD 20892-5452, (301) 594-7682,
pateldg@niddk.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.847,
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive
Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology
[[Page 63316]]
and Hematology Research, National Institutes of Health, HHS)
Dated: October 4, 2011.
Jennifer S. Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2011-26215 Filed 10-11-11; 8:45 am]
BILLING CODE 4140-01-P
